# US 2025/0123267 A1 · Inhibitors of microtubule polyglutamylation in mitosis for use as a medicament

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0123267 A1
- Document ID: US20250123267A1
- Status: Published application
- Kind: A1
- Application number: 18/711,500
- Filed: 2022-11-17
- Published: 2025-04-17
- Earliest claimed: 2021-11-18
- Assignees: Fundació Centre De Regulació GenòMica; Institució Catalana De Recerca I Estudis AvançAts
- Applicants: Fundació Centre De Regulació GenòMica; Institució Catalana De Recerca I Estudis AvançAts
- Inventors: Isabelle Vernos; Ivan Zadra
- Web page: https://patentgrep.com/patent/US20250123267A1

## CPC

- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/573: for enzymes or isoenzymes
- G01N 33/575: for cancer
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G01N 2333/9015: Ligases (6)
- G01N 2440/34: addition of amino acid(s), e.g. arginylation, (poly-)glutamylation, (poly-)glycylation
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention refers to inhibitors of microtubule polyglutamylation in mitosis for use as a medicament, preferably in the treatment of diseases benefiting from the inhibition of microtubule polyglutamylation in mitosis, most preferably in the treatment of cancer.

## Claims

### Claim 1

In vitro method for screening, identifying and/or producing compounds for treating a disease which comprises: a) Assessing TTLL11 enzyme activity once the candidate compound has been incubated with TTLL11 enzyme, and b) wherein if an inhibition of TTLL11 activity is observed, it is indicative that the candidate compound may be effective for treating a disease.

### Claim 2 (depends on 1)

In vitro method, according to claim 1, characterized in that the method is a non-radioactive assay wherein TTLL11 activity is assessed by analysing whether additional glutamates haven been incorporated by the enzyme TTLL11 to the enzyme substrate, wherein if no additional glutamates have been incorporated to the enzyme substrate this is an indication that the candidate compound has inhibited TTLL11 activity and may be effective as for treating a disease.

### Claim 3 (depends on 1)

In vitro method, according to claim 1, characterized in that TTLL11 activity is assessed by analysing whether additional glutamates haven been incorporated by the enzyme TTLL11 to the enzyme substrate by using an immunoassay or by mass spectrometry, wherein if no additional glutamates have been incorporated to the enzyme substrate this is an indication that the candidate compound has inhibited TTLL11 activity and may be effective for treating a disease.

### Claim 4 (depends on 1)

In vitro method, according to claim 1, characterized in that the enzyme substrate is a stabilized microtubule which has been obtained by tubulin polymerization and the activity of TTLL11 enzyme is assessed by analysing whether additional glutamates haven been incorporated by the enzyme TTLL11 to the enzyme substrate by using an immunoassay.

### Claim 5 (depends on 1)

In vitro method, according to claim 1, characterized in that the enzyme substrate is a peptide corresponding to the C-terminal region of tubulin and the activity of TTLL11 enzyme is assessed by analysing whether additional glutamates haven been incorporated by the enzyme TTLL11 to the enzyme substrate by mass spectrometry.

### Claim 6 (depends on 1)

In vitro method, according to claim 1, for screening, identifying and/or producing compounds for the treatment of diseases benefiting from the inhibition of microtubule polyglutamylation in mitosis.

### Claim 7 (depends on 1)

In vitro method, according to claim 1, for screening, identifying and/or producing compounds for the treatment of cancer.

### Claim 8

A method of treating a disease with inhibitors of microtubule polyglutamylation in mitosis.

### Claim 9 (depends on 8)

A method of treating disease with inhibitors of microtubule polyglutamylation in mitosis, according to claim 8, wherein the inhibitors are TTLL11 inhibitors.

### Claim 10 (depends on 8)

A method of treating disease with inhibitors of microtubule polyglutamylation in mitosis, according to claim 8, in wherein the disease is a disease benefiting from the inhibition of microtubule polyglutamylation in mitosis.

### Claim 11 (depends on 8)

A method of treating disease with inhibitors of microtubule polyglutamylation in mitosis, according to claim 8, wherein the disease is cancer.

### Claim 12 (depends on 8)

A method of treating disease with inhibitors of microtubule polyglutamylation in mitosis, according to claim 8, wherein the inhibitor is a biologic agent or a chemical compound.

### Claim 13 (depends on 8)

A method of treating disease with inhibitors of microtubule polyglutamylation in mitosis, according to claim 8, wherein the inhibitor is a small molecule.

### Claim 14 (depends on 8)

A method of treating disease with inhibitors of microtubule polyglutamylation in mitosis, according to claim 8, wherein the inhibitor is a siRNA.

### Claim 15 (depends on 8)

A method of treating disease with inhibitors of microtubule polyglutamylation in mitosis, according to claim 8, wherein the inhibitor is an ATP-competitive inhibitor.

### Claim 16

Pharmaceutical composition comprising an inhibitor of microtubule polyglutamylation in mitosis and, optionally, pharmaceutically acceptable carriers or excipients.

### Claim 17 (depends on 16)

Pharmaceutical composition, according to claim 16, comprising:
(a) a TTLL11 inhibitor and, optionally, pharmaceutically acceptable carriers or excipients;
(b) an inhibitor selected from a biologic agent or a chemical compound and, optionally, pharmaceutically acceptable carriers or excipients;
(c) a small molecule inhibitor and, optionally, pharmaceutically acceptable carriers or excipients;
(d) comprising a siRNA and, optionally, pharmaceutically acceptable carriers or excipients; or
(e) an ATP-competitive inhibitor and optionally, pharmaceutically acceptable carriers or excipients.

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

In vitro method for the diagnosis and/or prognosis of a disease benefiting from the inhibition of microtubule polyglutamylation in mitosis which comprises assessing the level of expression of TTLL11 in a biological sample obtained from the patient, wherein the identification of a reduced level of expression of TTLL11, as compared with a pre-established level of expression measured in healthy control patients, is as indication that the patient is suffering from a disease benefiting from the inhibition of microtubule polyglutamylation in mitosis.

### Claim 23 (depends on 22)

In vitro method, according to claim 22, for the diagnosis and/or prognosis of cancer which comprises assessing the level of expression of TTLL11 in a biological sample obtained from the patient, wherein the identification of a reduced level of expression of TTLL11, as compared with a pre-established level of expression measured in healthy control patients, is as indication that the patient is suffering from cancer.

### Claim 24

In vitro use of TTLL11 for the diagnosis and/or prognosis of a disease benefiting from the inhibition of microtubule polyglutamylation in mitosis.

### Claim 25 (depends on 24)

In vitro use of TTLL11, according to claim 24, for the diagnosis and/or prognosis of cancer.
